Shares of Aerovate Therapeutics, Inc. are down 90.1% following the release of poor top line results from its Phase 2b portion of IMPAHCT evaluating AV-101 for the treatment of pulmonary arterial hypertension. Block & Leviton is investigating whether the Company violated any securities laws in the lead up to this announcement.
Contact our attorneys for a no-cost case evaluation.